Supernus Pharmaceuticals | SUPN - Loan Capital


Supernus Pharmaceuticals reported $400.38M in Loan Capital for its fiscal quarter ending in March of 2022.





Loan Capital Change Date
Abbott USD 29.64B 19.74B Mar/2026
ANI Pharmaceuticals USD 280.15M 5.84M Jun/2026
Aurora Cannabis CAD 18.13M 15.07M Mar/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Canopy Growth CAD 217.12M 7.87M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Eisai JPY 184.6B 49.83B Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Novo Nordisk DKK 121.79B 2.62B Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.28B 337.7M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
United Therapeutics USD 100M 100M Jun/2024
Xeris Pharmaceuticals USD 188.81M 32.42M Jun/2026